Building HTA insights into the drug development plan: Current approaches to seeking early scientific advice from HTA agencies

There is a growing trend for pharmaceutical companies to seek scientific advice on drug development from a Health Technology Assessment (HTA) perspective, to improve the efficiency of their studies, enable better trial design, and support the goals of positive HTA recommendation for reimbursement. This study uses information collected directly from companies on individual products to assess their strategies and practices for seeking HTA-related scientific advice in terms of which stakeholders to engage and for what purpose, when to seek scientific advice, and whether to implement that advice within global clinical development.

Automated summary

There is a growing trend for pharmaceutical companies to seek scientific advice on drug development from a Health Technology Assessment (HTA) perspective, to improve the efficiency of their studies and support positive HTA recommendations. This study evaluates pharmaceutical companies' strategies and practices for seeking HTA-related scientific advice based on information collected directly from companies.